Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
00
Trial Sponsor
Clinical Trial Start Date
2022
0Primary Completion Date
2024
0Study Completion Date
2024
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Drug0
Device0
Intervention Name
INO-91120
CELLECTRA® 20000
INO-48000
Interventional Trial Phase
Phase 10
Official Name
Phase 1 Open Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Intradermal Booster Dose of INO-4800 Alone or in Combination With INO-9112 Followed by Electroporation, in Adults Who Completed a Primary Immunization Series Against SARS-CoV-2 With mRNA Vaccines0
Last Updated
November 17, 2022
0Allocation Type
Non-Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Study summary
This is an open label, phase 1 clinical trial of an intra-dermal booster dose of INO-4800 alone or in combination with INO-9112 followed by electroporation (EP) among healthy adults at least 18 years of age, who previously completed their primary immunization series with mRNA vaccines against SARS-CoV-2 within 6-12 months prior to the booster dose.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
